Posters
Ab-interno canaloplasty (ABiC) as a stand alone treatment and in combination with cataract surgery for treatment of primary open-angle glaucoma
Poster Details
First Author: M.Khaimi USA
Co Author(s):
Abstract Details
Purpose:
To compare the safety and efficacy of ab-interno canaloplasty (ABiC) in reducing intraocular pressure (IOP) and anti-glaucoma medication dependence in patients undergoing either a standalone ABiC procedure or a combined procedure of cataract surgery and ABiC.
Setting:
Dean McGee Eye Institute, University of Oklahoma School of Medicine, USA.
Methods:
Non-randomized, single-center study of patients with mild-to-moderate primary open-angle glaucoma (POAG) undergoing either ABiC or a combined procedure of cataract surgery and ABiC. Within the respective subsets, all eyes were analyzed for changes in mean IOP and median number of anti-glaucoma medications over a period of 12 months. Secondary endpoints included the incidence of intra- and postoperative complications.
Results:
In the standalone ABiC subset (n=29), mean IOP reduced from 21.0 �Â�± 5.8 mm Hg at baseline to 15.9 �Â�± 3.4 mm Hg at 12 months (p<0.001). Median medications reduced from 2 (range 1-4) to 1 (range 0-2). In the phaco-ABiC subset (n=57), mean IOP reduced from 17.9 �Â�± 5.2 mm Hg to 15.0 �Â�± 3.8 mm Hg (p=0.002), and median medications reduced from 2 (range 0-4) to 0 (range 0-2). There were no serious intra- or postoperative adverse events. Eighteen month results will be presented.
Conclusions:
ABiC is a safe and effective glaucoma procedure that provides a reduction in both IOP and anti-glaucoma medication dependence in patients with mild-to-moderate POAG, whether in a standalone procedure or when combined with cataract surgery.
Financial Disclosure:
receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
